v3.22.4
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2022
Cash flows from operating activities:          
Net earnings/(loss) $ (130) $ 49 $ (19) $ 321  
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:          
Depreciation and amortization     341 332  
(Gain)/loss on sale of equity interest in naviHealth 0 (1) 0 (1)  
Impairments and (gain)/loss on disposal of assets, net 710 1,295 863 1,293  
Loss on early extinguishment of debt 0 0 0 10  
Share-based compensation     48 42  
Provision for bad debts     59 25  
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:          
Increase in trade receivables     (919) (329)  
Increase in inventories     (1,643) (361)  
Increase in accounts payable     2,954 1,059  
Other accrued liabilities and operating items, net     (1,064) (1,842)  
Net cash provided by operating activities     620 549  
Cash flows from investing activities:          
Proceeds from divestitures, net of cash sold     0 938  
Additions to property and equipment     (155) (141)  
Proceeds from disposal of property and equipment     2 0  
Proceeds from investments     1 22  
Purchases of investments     (5) (4)  
Net cash provided by/(used in) investing activities     (157) 815  
Cash flows from financing activities:          
Reduction of long-term obligations     (13) (592)  
Net tax proceeds/(withholdings) from share-based compensation     9 (27)  
Dividends on common shares     (271) (289)  
Purchase of treasury shares     (1,250) (800)  
Net cash used in financing activities     (1,525) (1,708)  
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations     (1) (11)  
Cash and equivalents reclassified from/(to) assets held for sale     0 109  
Net decrease in cash and equivalents     (1,063) (246)  
Cash and equivalents at beginning of period     4,717 3,407 $ 3,407
Cash and equivalents at end of period $ 3,654 $ 3,161 $ 3,654 $ 3,161 $ 4,717